drugset / Trial / NCT06959745

Magnesium-L-Threonate Improves Menopausal Symptoms

NCT06959745 ↗

Not yet recruiting 50 enrolled Guangdong Provincial People's Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This trial has a randomized, single-blind, single-center, parallel-controlled design, with participant screening and trial implementation conducted at Guangdong Provincial People's Hospital. The study evaluate the efficacy of oral magnesium L-threonate supplementation on improving menopausal symptoms and quality of life among peri/post-menopausal women. This trial aims to explore whether oral magnesium L-threonate supplementation could alleviate menopausal syndromes. Participants will randomly assigned to conduct oral magnesium L-threonate supplementation or placebo for 8 weeks. Face-to-face and internet follow up will be conducted once per 2 weeks.

Timeline

Start
2025-05-15
Primary completion
2025-09-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium L-threonate Unknown 1740 mg Oral

Indications